Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

• Main Authors: Shaymaa E. Kassab (Author), Samar Mowafy (Author), Aya M. Alserw (Author), Joustin A. Seliem (Author), Shahenda M. El-Naggar (Author), Nesreen N. Omar (Author), Mohamed M. Awad (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity a...